Oncology, for colleagues, by colleagues.

Every week, and every day during the major congresses, the OncoAlert Newsletter brings curated trial updates, congress highlights and expert perspectives to 10,000+ oncologists and cancer stakeholders.

Get the OncoAlert Newsletter

Your role

Your country

How we use your details

Free. Easy to leave.

February 1–7, 2027. Every day at 6:00 PM CET / 12:00 PM EST. Free for oncology professionals.

Starts in 80 days, 18 hours and 1 minute.

ESMO 2026 Highlights

Madrid, October 23–27, 2026

Top 10 lists, 4Sights, Podium2Screen and On The Go.

See the ESMO 2026 highlights

Latest news

The latest regulatory decisions and trial results.

All news

Management of Patients with High-risk Localised, Locally Advanced, and Biochemically Recurrent Prostate Cancer: Report from the 2026 Advanced Prostate Cancer Consensus Conference
44 out of 134. That’s how often the world’s top prostate cancer experts agreed. The disagreements may matter even more.
The OncoAlert Network. Genitourinary. Trial result. European Urology. October 27, 2026.
Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer
A 0.42 hazard ratio for death in extensive-stage small-cell lung cancer. In a disease where we’ve celebrated gains of two to three months, this is a different level. In the open-label phase 3 DeLLphi-305 trial, 563 patients with extensive-stage SCLC without progression after first-line chemoimmunotherapy were randomized to tarlatamab plus durvalumab or durvalumab alone as maintenance. The median overall survival was 21.1 versus 12.7 months (HR 0.42), and the median PFS 7.4 versus 1.9 months (HR 0.34). Grade ≥3 adverse events occurred in 46.8% versus 40.6%; cytokine release syndrome, mostly grade 1–2, affected nearly half of tarlatamab-treated patients.
The OncoAlert Network. Lung and thoracic. Trial result. NEJM. October 30, 2026.
CheckMate 8HW final results: dual checkpoint inhibition in MSI-H/dMMR metastatic colorectal cancer
Final CheckMate 8HW results (68-month follow-up) demonstrate: OS benefit vs nivolumab across all treatment lines (HR 0.61) OS benefit vs chemotherapy in 1L (HR 0.37) Sustained PFS and response advantages No new safety signals A significant step forward for immunotherapy in mCRC.
The OncoAlert Network. Gastrointestinal. Trial result. Annals of Oncology. November 2, 2026.
Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC
A new phase 3 trial puts divarasib head-to-head against existing KRAS G12C inhibitors, with encouraging results. In previously treated KRAS G12C-mutated advanced NSCLC, divarasib significantly improved median progression-free survival (9.8 vs 5.7 months; HR 0.58) and overall survival (17.7 vs 12.0 months; HR 0.56) compared with sotorasib or adagrasib. Response rates were also higher (58.4% vs 32.3%), with fewer grade 3–4 treatment-related adverse events (24.6% vs 34.5%).
The OncoAlert Network. Lung and thoracic. Trial result. NEJM. November 3, 2026.
FDA NEWS | AZUR 1 Update in Rectal Cancer
FDA grants accelerated approval to dostarlimab (Jemperli) for previously untreated stage II/III dMMR/MSI-H locally advanced rectal cancer.First immunotherapy in this setting — may allow some patients to avoid chemo, radiation, and surgery.AZUR-1: 68% cCR12, 76% no evidence of disease ≥1 year, no recurrences in responders (median FU >2 yrs). Nearly ¾ of patients avoided surgery/RT/chemo
The OncoAlert Network. Gastrointestinal. Regulatory news. FDA. October 19, 2026.
Safety of combining radiation therapy and antibody-drug conjugates in patients with breast cancer: a systematic review and meta-analysis
This systematic review and meta-analysis of 29 studies involving 3,817 patients evaluated the safety of combining radiotherapy (RT) with antibody-drug conjugates (ADCs) in breast cancer. Severe extracranial toxicities were uncommon with T-DM1, T-DXd, and sacituzumab govitecan (SG). However, intracranial RT revealed a consistent radiation necrosis safety signal with T-DM1, not observed with T-DXd or SG. These findings inform clinical decision-making and support updated ESTRO consensus recommendations. Courtesy of mirrors of medicine
The OncoAlert Network. Breast. Study result. Radiotherapy & Oncology. October 15, 2026.
Cribriform and intraductal carcinoma in prostate cancer-implications for risk stratification and therapeutic decision making (REVIEW)
Intraductal carcinoma of the prostate (IDC) and invasive cribriform carcinoma are aggressive histological patterns associated with adverse pathology, metastasis, and prostate cancer mortality. Frequently underdetected on biopsy, they exhibit PTEN loss, genomic instability, DNA-repair alterations, and immunologically cold tumour microenvironments. Although these features suggest potential biomarker-directed therapies, evidence remains insufficient. Standardized reporting, improved detection, and prospective studies are essential to guide risk stratification and treatment decisions.
The OncoAlert Network. Genitourinary. Study result. Nature Reviews Urology. October 15, 2026.
Atezolizumab approved with fluoropyrimidine + oxaliplatin for adjuvant Stage III dMMR Colon Cancer (adults & peds ≥2 yrs).
Subcutaneous Tecentriq Hybreza also approved (≥12 yrs, ≥40 kg). Approval based on ATOMIC (NCT02912559): DFS HR 0.50 (95% CI 0.35–0.73; p=0.0001). 3-yr DFS ~86.3% vs 76.2%. Median DFS NR either arm.
The OncoAlert Network. Gastrointestinal. Regulatory news. FDA. October 12, 2026.

4Sight

ESMO 2026: the key abstracts.

All ESMO 2026 4Sights

CLARITY-Gastric 01
Gastrointestinal
SAFFRON
Lung and thoracic
Krascendo 1
Lung and thoracic
DASL-HiCaP (ANZUP1801)
Genitourinary
DeLLphi-305
Lung and thoracic
VOLGA
Genitourinary
LBA1
Melanoma and skin
FLAURA2
Lung and thoracic
459O
Gastrointestinal
4736O
Genitourinary
4449RO
Breast
PEARLS/KEYNOTE-091
Lung and thoracic

97 colleagues at the table

Oncologists, nurses, researchers and patient advocates. Every round-up, pick and interview names the colleague who presented it.

All faculty

Dr. Gil Morgan
The OncoAlert Network
Clinical oncology
Dr. Neeraj Agarwal
Huntsman Cancer Institute, Utah
Genitourinary cancers
Dr. Fabrice André
Gustave Roussy / Paris Saclay
Breast cancer
Dr. Andrés Cervantes
University of Valencia
GI oncology
Dr. Toni Choueiri
Dana-Farber / Harvard
Genitourinary cancers
Dr. Giuseppe Curigliano
European Institute of Oncology, Milan
Cancer research
Dr. Cathy Eng
Vanderbilt-Ingram Cancer Center
GI oncology
Dr. Silke Gillessen
Univ. of Manchester / The Christie
Genitourinary cancers
Dr. Julie R. Gralow
ASCO
Breast cancer
Dr. Erika Hamilton
Sarah Cannon Research Institute
Breast cancer
Dr. Matteo Lambertini
IRCCS San Martino / U Genova
Breast cancer
Dr. Sherene Loi
Peter Mac, Melbourne
Breast cancer
Dr. Christine Lovly
Vanderbilt University
Thoracic oncology
Dr. Declan Murphy
Peter MacCallum Cancer Centre
Genitourinary cancers
Dr. Solange Peters
Lausanne University
Thoracic oncology
Dr. Sanjay Popat
Royal Marsden / Imperial College
Thoracic oncology
Dr. Tom Powles
Barts Cancer Centre, London
Genitourinary cancers
Dr. Brian Rini
Vanderbilt-Ingram Cancer Center
Genitourinary cancers
Dr. Hope Rugo
UCSF Helen Diller
Breast cancer
Dr. Sara Tolaney
Dana-Farber / Harvard
Breast cancer
Meet all 97 faculty

The OncoAlert Colloquium 2027

The seventh annual year in review in oncology, February 1–7, 2027: one tumor group a day, every day at 6:00 PM CET / 12:00 PM EST, in a multidisciplinary format. Free for oncology professionals; registration is open.

Genitourinary oncologyDay 1. Monday, February 1. 8 talks. Moderated by Dr. Gil Morgan.Program day 1, Genitourinary oncology
Breast cancerDay 2. Tuesday, February 2. 11 talks. Moderated by Dr. Elisa Agostinetto and Dr. Gil Morgan.Program day 2, Breast cancer
Gastrointestinal oncologyDay 3. Wednesday, February 3. 9 talks. Moderated by Dr. Joseph McCollom and Dr. Gil Morgan.Program day 3, Gastrointestinal oncology
Gynecologic oncology (ESGO-led day)Day 4. Thursday, February 4. 10 talks.Program day 4, Gynecologic oncology (ESGO-led day)
Lung cancer and supportive careDay 5. Friday, February 5. 8 talks. Moderated by Dr. Gil Morgan and Dr. Oriol Mirallas.Program day 5, Lung cancer and supportive care
Miscellaneous and hematologic malignanciesDay 6. Saturday, February 6. 5 talks.Program day 6, Miscellaneous and hematologic malignancies
“How I treat when options are limited” (global oncology)Day 7. Sunday, February 7. 4 talks.Program day 7, “How I treat when options are limited” (global oncology)

OncoAlert Horizons

OncoAlert’s educational series: two experts on one evolving question in practice, a focus at a time.

Supported by an unrestricted educational grant from Roche. All content was independently developed and fully controlled by the faculty.

Adjuvant treatment challenges in early HR+/HER2− breast cancer: the emerging role of next-generation oral SERDs

Dr. Sibylle Loibl and Dr. Rupert Bartsch

Newest episode. June 15, 2026. 14 minutes.

Watch the episode

Earlier episodes

The series

The new sequencing challenge in HER2+ metastatic breast cancerDr. Javier Cortés and Dr. Elisa AgostinettoJune 10, 2026. 17 minutes.
Early HER2+ breast cancer: escalate, de-escalate or personalize?Dr. Giampaolo Bianchini and Dr. François-Clément BidardMay 26, 2026. 20 minutes.
What comes after CDK4/6 inhibitors? SERDs, combinations and the future of HR+ advanced breast cancerDr. Sherene Loi and Dr. Elisa AgostinettoMay 20, 2026. 14 minutes.

Free, and independent

OncoAlert began in 2019 as a voluntary network of oncologists and patient advocates, and has been a registered non-profit NGO since 2023. It has no conflict of interest. Everything here is free for oncology professionals. We accept up to two unrestricted educational grants a year, and all content is 100% independent: the experts and OncoAlert create it, with no influence from the supporters.

About OncoAlert How we are funded

Partners and collaborators

Unrestricted educational grants, 2026

The OncoAlert Colloquium, 2026

Unrestricted Non-promotional educational support (all supported equally)

The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.

Email address

Your role

Your country

How we use your details

Oncology, for colleagues, by colleagues.

The OncoAlert Colloquium 2027

ESMO 2026 Highlights

Latest news

4Sight

97 colleagues at the table

The OncoAlert Colloquium 2027

OncoAlert Horizons

Earlier episodes

Free, and independent

Partners and collaborators

Unrestricted educational grants, 2026

The OncoAlert Colloquium, 2026

The week in oncology, in your inbox